NILK-3301
CEACAM5 (CEA)-expressing solid tumors
PreclinicalActive
Key Facts
About LamKap Bio
LamKap Bio is a private, preclinical-stage biotech developing a pipeline of bispecific antibodies targeting solid tumors. Its core technology is the κλ-body platform, which enables the creation of fully human, multispecific antibodies designed to be 'truly natural' to potentially improve safety and efficacy. The company's most advanced program, NILK-2301 (CEA x CD3), has entered Phase 1 clinical trials, positioning it as an emerging player in the competitive T-cell engager and macrophage-redirection space for oncology.
View full company profileTherapeutic Areas
Other CEACAM5 (CEA)-expressing solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NILK-2301 | LamKap Bio | Phase 1 |
| NILK-2401 | LamKap Bio | IND/CTA-enabling |